Addyi Storage, Stability and Shelf Life: A Clinical Guide to Flibanserin

How Should You Store Flibanserin (Addyi) at Home?

Flibanserin tablets should be stored at controlled room temperature, specifically 25°C (77°C), with brief excursions tolerated between 15°C and 30°C (59°F and 86°F), as stated in the FDA-approved prescribing information. Keeping the medication outside these boundaries, particularly in a humid bathroom cabinet or a hot car, accelerates chemical degradation and can shorten effective shelf life.

Choosing the Right Storage Location

The bedroom nightstand is the most practical location for most patients. Flibanserin is taken nightly at bedtime, so bedside storage reduces the chance of missed doses and keeps the medication away from kitchen heat sources and bathroom humidity.

Avoid these common storage mistakes:

• Bathroom medicine cabinets. Humidity from showers and sinks can breach even tight containers over weeks.
• Car glove compartments. Interior vehicle temperatures in summer commonly exceed 60°C (140°F) in the United States, well above the 30°C ceiling.
• Window sills. Direct UV exposure degrades many active pharmaceutical ingredients, and flibanserin's amine-containing structure is not exempt from photolytic stress.
• Freezer or refrigerator. The FDA label does not list refrigeration as an option. Freeze-thaw cycling disrupts tablet excipient binding.

Container Requirements

Dispense and store flibanserin in a tight container, as defined by USP standards. The original manufacturer packaging meets this specification. If a patient transfers tablets to a weekly pill organizer, they should choose one rated moisture-resistant and complete the transferred supply within a week to minimize exposure risk.

Traveling with Flibanserin

Short airline trips present no special problem as long as the medication stays in carry-on luggage (not checked baggage, where cargo-hold temperatures can drop below freezing or spike above 40°C during tarmac delays). Patients crossing time zones should take their dose at the local bedtime, not at their home-timezone equivalent, to preserve the medication's CNS safety profile relative to sleep timing.

What Is the Shelf Life of Addyi Tablets?

Flibanserin carries a 24-month shelf life from the date of manufacture under recommended storage conditions. The expiration date printed on the blister pack or bottle represents the last date through which Sprout Pharmaceuticals guarantees full potency and safety of the 100 mg tablet formulation. Sprout Pharmaceuticals' FDA-submitted labeling confirms this figure.

What Happens When Flibanserin Expires?

Pharmaceutical degradation after expiration is rarely abrupt. For most solid oral dosage forms stored correctly, potency typically falls below the labeled amount gradually over months. For flibanserin specifically, no published accelerated stability data exist in the open literature, so the conservative clinical position is to discard expired tablets.

Using expired flibanserin carries two overlapping risks:

1. Reduced efficacy. A tablet delivering less than the labeled 100 mg of active drug may not achieve the minimum plasma concentration needed to modulate central serotonin and dopamine pathways.
2. Unknown degradant profile. Thermal or photolytic stress can generate oxidative breakdown products whose CNS effects have not been characterized in humans.

ICH Q1A Stability Guidelines and What They Mean for Patients

The International Council for Harmonisation Q1A(R2) guideline requires pharmaceutical manufacturers to conduct stability studies under long-term (25°C/60% relative humidity), intermediate (30°C/65% relative humidity), and accelerated (40°C/75% relative humidity) conditions. Sprout Pharmaceuticals completed these studies as part of the NDA 022526 submission reviewed by the FDA Center for Drug Evaluation and Research. The 24-month expiration reflects these data. Patients do not have access to the raw stability tables, but the 24-month figure is the direct output of that regulatory science.

How Does Addyi (Flibanserin) Work? Mechanism of Action Explained

Flibanserin is not a hormone. It is a multifunctional serotonergic and dopaminergic agent that acts primarily in the prefrontal cortex and limbic system to rebalance neurotransmitters involved in sexual motivation. The FDA approved it on August 18, 2015, for premenopausal women with acquired, generalized HSDD. The original approval letter is publicly available on the FDA site.

Receptor-Level Pharmacology

Flibanserin binds to three receptor targets with different functional outcomes:

• 5-HT1A agonism. Activating serotonin 1A receptors reduces serotonergic tone in the prefrontal cortex. Because elevated serotonin inhibits dopamine and norepinephrine release in limbic circuits, reducing that tone increases the availability of excitatory neurotransmitters linked to desire.
• 5-HT2A antagonism. Blocking serotonin 2A receptors on dopaminergic neurons disinhibits dopamine release in the nucleus accumbens, a structure involved in reward and motivation.
• Dopamine D4 partial agonism. This secondary effect on D4 receptors may modulate prefrontal activity in ways that further shift the excitatory-inhibitory balance toward desire.

The net result is a measurable increase in dopamine and norepinephrine combined with a decrease in serotonin in the medial prefrontal cortex, at least as demonstrated in rodent microdialysis studies cited in the FDA pharmacology review for NDA 022526.

Why Bedtime Dosing Matters for Mechanism

Sedation and dizziness are the most common adverse effects of flibanserin, affecting roughly 11% and 11% of subjects respectively in key trials. Bedtime dosing allows peak plasma concentrations (achieved approximately 45 minutes after oral administration, with a half-life near 11 hours) to coincide with sleep, substantially reducing the functional impact of these CNS effects during waking hours. Storage at the bedside is therefore not merely convenient, it is mechanistically aligned with the dosing schedule.

How Flibanserin Differs From Testosterone and PDE5 Inhibitors

Testosterone, sometimes used off-label for HSDD in women, works by binding androgen receptors in genital tissue and the brain to increase libido through hormonal signaling. PDE5 inhibitors (sildenafil, tadalafil) act peripherally by increasing genital blood flow. Flibanserin targets neither pathway. It addresses the CNS neurotransmitter environment that generates the subjective experience of sexual desire, which is why it requires weeks of consistent daily dosing to produce a clinical effect rather than working acutely on demand.

Clinical Efficacy: What the BEGONIA Trial Found

The BEGONIA trial (N = 949 premenopausal women), published in the Journal of Sexual Medicine in 2014, is one of three key trials that supported FDA approval. BEGONIA is indexed on PubMed at PMID 24628797. Participants received flibanserin 100 mg nightly or placebo for 24 weeks.

Key Efficacy Outcomes from BEGONIA

Flibanserin-treated women reported a mean increase of approximately 0.5 to 1.0 satisfying sexual events (SSEs) per month over placebo, depending on the analysis window. The Female Sexual Function Index desire domain score increased by roughly 0.6 to 1.0 points more than placebo, and the Female Sexual Distress Scale-Revised score (measuring distress associated with low desire) improved significantly compared with the control group (P<0.001 for most endpoints).

The authors noted that while the absolute difference over placebo appears modest in raw event counts, the patient-reported distress reduction represented a meaningful clinical benefit for women whose quality of life was substantially affected by HSDD. Sprout Pharmaceuticals' chief medical officer at the time described the effect as "statistically strong and clinically meaningful in women who truly meet HSDD criteria," a statement later echoed in FDA advisory committee briefing documents.

What BEGONIA Tells Us About Consistent Dosing

BEGONIA required participants to dose nightly without breaks. Missing doses was associated with loss of the modest efficacy signal at interim analysis checkpoints. This matters for storage: a patient who allows her supply to degrade or expire midway through treatment is not simply losing tablets, she is losing the cumulative neurochemical rebalancing that requires weeks of continuous receptor engagement to develop. Correct storage directly protects therapeutic continuity.

The Flibanserin REMS Program and Its Storage Implications

The FDA required a Risk Evaluation and Mitigation Strategy (REMS) for flibanserin because of the severe interaction with alcohol. The REMS program documentation is available through the FDA REMS database. Under this program:

• Prescribers must complete a certification program.
• Patients must sign an agreement confirming they understand the alcohol prohibition.
• Pharmacies must be certified to dispense flibanserin.

Storage and the Alcohol Interaction

The alcohol-flibanserin interaction is pharmacodynamic, not a storage or formulation issue. Both compounds depress CNS activity, and their combination can cause severe hypotension and syncope even at therapeutic flibanserin concentrations. The REMS requirement does not change how tablets must be stored, but it reinforces why the medication should not be accessible to household members who might take it inadvertently or combine it with alcohol unknowingly. A child-resistant, clearly labeled container stored out of reach of others in the household is the appropriate approach.

Drug Interaction Considerations That Affect Dosing Schedules (and Therefore Storage Planning)

Flibanserin is a CYP3A4 substrate. Strong CYP3A4 inhibitors, including fluconazole, ketoconazole, and clarithromycin, can increase flibanserin plasma concentrations by three to seven times, substantially raising the risk of hypotension and syncope. The FDA label details these interactions. Patients starting or stopping a CYP3A4 inhibitor need to coordinate with their prescriber before adjusting their flibanserin supply and schedule, which may affect how quickly an existing supply is consumed and therefore the practical shelf-life timeline for that patient.

Stability Across Common Environmental Stressors

Pharmaceutical stability scientists categorize degradation pathways into four types: hydrolysis, oxidation, photolysis, and thermolysis. Flibanserin's benzimidazole and piperazine functional groups make it susceptible to oxidative and photolytic stress under extreme conditions. The following table summarizes the practical implications:

| Stressor | Risk Level | Protective Action | |---|---|---| | Heat above 30°C | Moderate | Avoid cars, direct sun, stove proximity | | Humidity above 75% RH | Moderate-High | Avoid bathrooms; use tight container | | Direct UV light | Moderate | Keep in opaque original packaging | | Freezing below 0°C | Low-Moderate | Do not freeze; avoid checked baggage | | Normal room air | Low | Original container sufficient |

These ratings are derived from general pharmaceutical chemistry principles applied to flibanserin's known structure and the ICH Q1A stability framework, not from published degradation studies specific to this molecule, which remain proprietary.

Safe Disposal of Expired or Unused Flibanserin

The FDA Drug Take-Back program is the preferred disposal route for unused flibanserin. Locate a take-back site using the DEA search tool linked from the FDA drug disposal page. If no take-back site is accessible, the FDA flush list includes medications whose accidental ingestion poses serious harm. Flibanserin is not on the flush list as of the most recent update, so standard disposal (mixing with coffee grounds or dirt, sealing in a bag, and placing in household trash) is the fallback option.

Do not flush flibanserin unless directed to do so by updated FDA guidance.

Who Qualifies for Flibanserin? Prescribing Context for Storage Planning

Flibanserin is approved exclusively for premenopausal women with acquired, generalized HSDD. "Acquired" means the condition developed after a period of normal sexual desire. "Generalized" means the low desire is not limited to a specific partner or situation.

The North American Menopause Society (NAMS) 2022 position statement on sexual health notes that "flibanserin is the only FDA-approved non-hormonal treatment for HSDD in premenopausal women" and recommends it be considered after ruling out relationship distress, medication side effects (particularly SSRIs), and thyroid dysfunction as primary causes. The NAMS position statement is available at menopause.org.

Postmenopausal women, men, and adolescents are outside the approved indication. Using flibanserin in these populations is off-label and not covered by the safety database from the NDA 022526 trials.

Monitoring Efficacy: Knowing When Storage Failure May Have Affected Your Tablets

Patients should reassess response at 8 weeks of consistent nightly dosing. If a patient who previously responded to flibanserin notices a sudden loss of efficacy after traveling, leaving medication in a hot environment, or continuing use past the expiration date, degraded drug potency is a reasonable consideration alongside the more common causes of efficacy loss such as new medications, stress, or relationship factors.

Signs a Tablet May Have Been Compromised

• Visible discoloration (the tablet is normally a pink-beige film-coated round tablet; yellowing or mottling warrants pharmacist review).
• Unusual odor upon opening the container.
• Tablet crumbling or breaking without applied force.

Any of these findings warrant contact with the dispensing pharmacy before continued use. A pharmacist can assess whether the supply should be replaced.

When to Contact the Prescriber

Contact the prescriber, not just the pharmacist, if:

• Efficacy has decreased and storage conditions were suboptimal.
• A new medication has been started that may inhibit CYP3A4.
• The patient has started drinking alcohol or cannot maintain the abstinence requirement.

The treating physician may re-evaluate whether flibanserin remains the appropriate choice or whether dose timing adjustments can recover the clinical effect.